Trial Profile
Evolocumab in Acute Coronary Syndrome: A Double-Blind Randomized Placebo Controlled Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Acute coronary syndromes; Myocardial infarction
- Focus Therapeutic Use
- Acronyms EVACS; EVACS-I
- 25 Oct 2023 Planned End Date changed from 25 Oct 2023 to 25 Apr 2024.
- 25 Oct 2023 Planned primary completion date changed from 25 Oct 2023 to 25 Apr 2024.
- 26 Aug 2023 According to an Amgen media release, data this study of olpasiran, presented in a late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam.